Emcure Pharmaceuticals Ltd and Sanofi India Ltd have announced an exclusive agreement under which Emcure will distribute and promote Sanofi India's portfolio of oral anti-diabetic (OAD) medicines across India, effective immediately.
As part of the deal, Emcure will take over the distribution and promotional responsibilities for well-known Sanofi brands such as Amaryl and Cetapin. However, Sanofi India will retain full ownership and continue manufacturing these products at its facilities in India and abroad.
Emcure’s MD and CEO Satish Mehta commented, “With our extensive distribution network, we aim to make Sanofi’s trusted OAD therapies more accessible to patients across the country. This partnership enhances our existing diabetes portfolio, allowing us to deliver a more comprehensive solution for diabetes care in India.”
Eric Mansion, General Manager – Pharma Southeast Asia and India & MCO Lead at Sanofi, added, “With Emcure’s strong nationwide reach, we’re confident in unlocking the full growth potential of our flagship OAD brands, Amaryl and Cetapin. This collaboration will benefit patients as well as the healthcare professionals who rely on these proven treatments.”
The companies clarified that the agreement does not involve any employee transfers from Sanofi India to Emcure.